ASK REDCHAT ANYTHING ABOUT CLIMB BIO, INC.
Climb Bio, Inc. (NASDAQ: CLYM)
Listen to this Section
$10.80
-0.1100
(
-1.01% )
570.5K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| BudoprutugDetailsKidney disease, Primary Membranous Nephropathy |
Phase 1b |
| ETX-123 (Kv7.2/3 channel opener)DetailsEpilepsy, Seizures, Pain |
Failed |
| ETX-155DetailsMajor depressive disorder, Perimenopausal Depression |
Failed |
| ETX-810DetailsChronic pain, Sciatica , Pain, Diabetes |
Failed |
| ETX-155DetailsEpilepsy |
Failed |
| ETX-810DetailsChronic pain, Pain, Sciatica |
Failed |
Market Data
|
| Open |
$10.80 |
| Previous Close |
$10.91 |
| Volume |
570.5K |
| Market Cap |
$624.74M |
| Day Range |
$10.47 - $11.63 |
| 52 Week Range |
$1.16 - $12.48 |
| Shares Outstanding |
57.26M |
| Change % |
-1.01% |
| Net Change |
▼ -0.1100 |
| Insider Ownership |
0.00% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | PHARMACEUTICAL PREPARATIONS |
| IPO Year | 2021 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
0.00
| Date |
Type |
Amount Purchased |
Purchaser |
| No records found. |
SEC Filings
No data available for selected period.